Semax and Selank: Enkephalin-Degrading Enzyme Research

Compound identity and research context

Semax is a synthetic peptide analogue based on a fragment of adrenocorticotropic hormone (ACTH). Selank is a synthetic analogue of tuftsin. These structural relationships distinguish the compounds; they do not establish equivalent activity to their parent peptides, selective action in the brain, or an absence of adverse effects.

Peptides are chains of amino acids. Their sequence, chemical form, degradation products, and experimental environment can affect laboratory measurements. Small peptide size alone does not establish blood–brain barrier penetration, receptor selectivity, or stability in a biological matrix.

Enkephalins and their degradation

Enkephalins are endogenous opioid peptides. Enkephalin degradation can involve more than one peptidase, so the term “enkephalinase” should not automatically be treated as the name of a single experimental target. A study should identify whether it measures a defined enzyme, a mixture of enzymes, or net substrate degradation in a biological matrix.

Reduced substrate degradation is not, by itself, proof of direct binding to a particular enzyme. It also does not demonstrate increased enkephalin abundance in brain tissue. Assigning a mechanism requires experiments that distinguish enzyme inhibition from competing substrates, matrix effects, and analytical interference.

What the supplied literature can support

The supplied citation for Kost and colleagues (2001), “Semax and selank inhibit the enkephalin-degrading enzymes of human serum,” reports inhibition in a human-serum experimental system [1]. This is an in-vitro context involving human-derived material, not evidence from administration to human participants. The supplied material does not include the assay protocol, numerical results, or enzyme-specific measurements needed to establish comparative potency or inhibition kinetics.

The supplied citation for Uchakina and colleagues (2008) identifies a human patient population [6]. It is therefore distinct from an in-vitro serum study. No clinical outcomes from that citation are used here to characterize laboratory materials or recommend their use.

Other supplied references address behavioral, hippocampal-expression, enzyme, receptor, or peptide-synthesis topics. Their bibliographic descriptions do not consistently identify the species, preparation, experimental conditions, or endpoints needed for a model-specific account. Findings from those references are not summarized here without that information. In particular, unspecified experimental studies should not be relabeled as animal, cell-based, or in-silico evidence.

The bibliography is reproduced as supplied and has not been independently verified for this revision. Before relying on an individual reference, researchers should confirm that its title, bibliographic details, and identifier correspond to the same publication and examine its methods and results. No quantitative potency, duration, or selectivity claim is established by the information supplied with this article.

Designing an interpretable nonclinical enzyme assay

The following are general experimental-design considerations, not a reconstruction of the cited studies or a validated protocol for Alpha Carbon Labs materials.

• Define the system: Identify the enzyme preparation or biological matrix, its source, the substrate, and the measured degradation products.
• Document assay conditions: Record buffer composition, pH, temperature, incubation interval, and analytical method. A comparison between compounds requires matched conditions.
• Include appropriate controls: Substrate-only, matrix or enzyme blanks, and compound-only controls can help distinguish degradation from background signals or analytical interference.
• Measure the relevant endpoint: Substrate disappearance and product formation provide different information. A change in detector signal should not automatically be interpreted as enzyme inhibition.
• Examine time dependence: Distinguish an initial reaction rate from an endpoint measurement. Assess whether degradation of the test peptide complicates interpretation.
• Report uncertainty: Document independent experiments, technical replicates, variability, and the assumptions used for any kinetic analysis.

Results from a defined enzyme preparation and results from serum answer different questions. Neither alone establishes activity in intact neural tissue. Likewise, a molecular-expression endpoint cannot substitute for a behavioral endpoint, and a behavioral observation does not identify a biochemical mechanism without additional evidence.

Mixtures require separate characterization

The Semax + Selank Blend is a separate material listing, not evidence of a combined mechanism. Results for individual compounds cannot establish mixture composition, activity, or synergy. Any nonclinical comparison involving a mixture would require verified component identity and appropriate individual-component controls.

Analytical documentation and laboratory handling

Review available certificates of analysis alongside the applicable quality-control documentation. Record the lot identifier, declared chemical form, analytical methods, and results relevant to the experiment. General information about peptide synthesis does not replace lot-specific characterization.

Mass spectrometry can support molecular identity, but a mass measurement alone does not establish sequence accuracy, purity, or concentration. Chromatographic purity is method-dependent and should not be treated as interchangeable with peptide content. No lot-specific identity results, purity values, stability data, or hazard classifications were supplied for this article.

Use the applicable safety data sheet and institutional risk assessment to determine handling controls, personal protective equipment, storage, and waste disposal. Human-derived serum requires the institution's biological-material precautions. Unknown hazards should not be interpreted as evidence of safety, and storage conditions or shelf life should not be inferred solely from peptide identity.

References supplied with the article

1. Kost, N. V., et al. (2001). Semax and selank inhibit the enkephalin-degrading enzymes of human serum. Peptides, 22(9), 1433-1438. — https://pubmed.ncbi.nlm.nih.gov/11516947/
2. Seredenin, S. B., et al. (1998). Anxiolytic effects of Semax and Selank in stress-induced behavior. Neuroscience and Behavioral Physiology, 28(5), 560-565. — https://pubmed.ncbi.nlm.nih.gov/9855584/
3. Zozulya, A. A., et al. (2001). The inhibitory effect of Selank on enkephalinase activity. Bulletin of Experimental Biology and Medicine, 131(4), 315-317. — https://pubmed.ncbi.nlm.nih.gov/11486241/
4. Dmitrieva, V. G., et al. (2010). Semax and Selank as modulators of Brain-Derived Neurotrophic Factor (BDNF) expression in the hippocampus. Neurochemistry International, 56(4), 519-524. — https://pubmed.ncbi.nlm.nih.gov/20045437/
5. Dolotov, O. V., et al. (2006). Semax prevents stress-induced behavioral changes and protects against neurotoxicity. European Journal of Pharmacology, 544(1-3), 22-26. — https://pubmed.ncbi.nlm.nih.gov/16814282/
6. Uchakina, O. N., et al. (2008). Immunomodulatory effects of Selank in patients with anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 41-45. — https://pubmed.ncbi.nlm.nih.gov/18577961/
7. Asmarii, M. R., et al. (1997). ACTH analogues and their impact on learning, memory, and cognitive stability. Peptides, 18(6), 843-847. — https://pubmed.ncbi.nlm.nih.gov/9280145/
8. Kozlovskaya, M. M., et al. (2003). Selank and GABA receptor modulation in experimental anxiety models. Experimental and Clinical Pharmacology, 66(4), 10-13. — https://pubmed.ncbi.nlm.nih.gov/12964528/
9. Roques, B. P., et al. (1993). Enkephalin-degrading enzymes as therapeutic targets in the central nervous system. Pharmacological Reviews, 45(1), 87-146. — https://pubmed.ncbi.nlm.nih.gov/8389445/
10. Gudasheva, T. A., et al. (1998). Synthesis and anxiolytic activity of Tuftsin analogues. European Journal of Medicinal Chemistry, 33(4), 273-282. — https://pubmed.ncbi.nlm.nih.gov/10898516/